The public healthcare AI market is emerging as a new growth engine. Medical AI specialist Coreline Soft, led by CEO Kim Jin-guk, announced on August 12th that it has officially signed a supply agreement with Seoul Boramae Medical Center’s Pulmonology Department to provide three AVIEW chest specialty products. This contract involves the introduction of various products—AVIEW COPD, AVIEW LCS Plus, and ILD—each designed for different purposes and formats, marking a notable case of an integrated model linking diagnosis, clinical practice, and research within Korea’s public healthcare AI adoption framework.
Amidst the active restructuring of the digital health policy environment led by the government and the expansion of healthcare AI reimbursement policies, Boramae Medical Center stands out as a leading public hospital under Seoul City, established by Seoul Metropolitan Government and operated under the supervision of Seoul National University Hospital. The hospital actively combines public service and research activities. The adoption of these AI solutions is expected to enhance the hospital’s multi-disease response capacity and contribute to the expansion of clinical research utilizing public healthcare data.
AI-Based Multi-disease Diagnosis and Research Integration Model
The three AVIEW chest products introduced by Coreline Soft are specialized for diagnosing chronic obstructive pulmonary disease (COPD), lung cancer and nodule detection (LCS), and interstitial lung disease (ILD). They feature automatic analysis based on low-dose chest CT scans and provide quantitative assessment functions. A representative from Coreline Soft stated, “We have maintained ongoing research collaborations with Boramae Medical Center, and after thorough verification of effectiveness in real clinical environments and data integration structures, we have decided to proceed with full-scale deployment. We also anticipate future joint academic achievements through diagnostics, multi-disciplinary research, and publications.”
Building Public Hospital AI Transition Models
Since 2017, Coreline Soft has been engaged in the national lung cancer screening quality management and information system project for nine consecutive years. With accumulated clinical quality and operational experience, the company has recently secured key projects in various European countries. The company was selected as the final implementer of the “AI-based Medical System Digital Transformation Support Project,” and through a two-year project worth a total of 2.32 billion won, it built Korea’s first ‘4-in-1’ chest AI diagnostic platform for public medical centers, successfully entering the public healthcare network.
The growth potential of Korea’s public healthcare AI market is significant. According to MarketandMarket, the global healthcare AI market is expected to grow from approximately 22 trillion won in 2025 to about 144 trillion won in 2030, with an average annual growth rate of 38.6%. Korea’s AI healthcare market is projected to grow even faster at a rate of 50.8%, reaching $6.672 billion (approximately 9.25 trillion won) by 2030.
Leveraging its extensive experience in supplying AI solutions to major public hospitals such as the National Cancer Center and Seoul National University Hospital, Coreline Soft aims to establish a definitive model for AI transformation within Korea’s public healthcare sector.
